John Garthwaite - Curriculum vitae#

• University of Surrey, 1968-72. BSc. (Hons) Biochemistry (Medical), 1972
• University of London, 2nd MB BS Pharmacology, 1973
• University of London, 1973-76 (St. Bartholomew's Hospital Medical College and School of Pharmacy), PhD Pharmacology, 1977

• Professor of Experimental Neuroscience, The Wolfson Institute for Biomedical Research, University College London.

• 1973-76: Research Associate, Dept. Pharmacology, St. Bartholomew's Hospital Medical College and School of Pharmacy, London.
• 1976-80: Research/Scientific Officer, MRC Developmental Neurobiology Unit, Carshalton, Surrey and Institute of Neurology, London.
• 1980-87: Lecturer in Physiology, Dept. Veterinary Physiology and Pharmacology, University of Liverpool.
• 1987-92: Lecturer, Senior Lecturer, Reader and then Professor (personal chair), Department of Physiology, University of Liverpool.
• 1992-95: Head of Neuroscience Research, Wellcome Research Laboratories, Beckenham, Kent.

• 1988-1991 National Committee & Treasurer, Brain Research Association.
• 1990-2007 Editorial Board, Journal of Neurochemistry.
• 1992-2005 Editorial Board, Neuroscience.
• 1992-date Executive Editor, Neuropharmacology.
• 1994-date Receiving Editor, European Journal of Neuroscience.
• 1995-1997 Grants Committee, International Human Frontiers Science Program (vice- chairman, 1997)
• 1995-1997 Medical Research Council Neurosciences, Mental Health and Cognitive Behaviour Panel, ROPA awards.
• 1997-2002 Scientific Advisory Committee, Epilepsy Research Foundation.
• 1997-2001 Medical Research Council Neurosciences and Mental Health Board representative.
• 1999-2001 Medical Research Council Advisory Board; non-clinical research training awards.
• 2003-date Scientific Advisory Board, The Swammerdam Institute for Life Sciences, Amsterdam, The Netherlands.
• 2003 Expert Committee, Canada Foundation for Innovation (Toronto).
• 2004-date Expert Review Group, Translation Awards, The Wellcome Trust
• 2004-date Chairman, IUPHAR sub-committee on “Nitric Oxide Receptors”
• 2009 Agence Nationale de la Recherche (ANR) grants committee, INSERM, France
• 2009-date Review Editor, Frontiers in Synaptic Neuroscience.
  

• 1988-1992: Consultant to Marion Merrill Dow, Inc., Kansas City, Missouri, U.S.A.
• 1992-1995: Head of the Neuroscience Therapeutic Area in the Wellcome Research Laboratories (Beckenham). The principal disease targets were neurodegeneration, pain and epilepsy.
• 1998-2000: Director of CereXus Ltd, a joint venture established between the pharmaceutical company “Cerebrus Ltd.” and The Wolfson Institute for Biomedical Research. This was aimed at the identification of novel agents acting on voltage-dependent sodium channels for protecting brain cells in stroke and head injury.
• 2000-2002: Collaborative programme with Vernalis Ltd. following their purchase of CereXus.
• 2003- date: Director of ProAxon Ltd, a spin-out company of the Wolfson Institute for Biomedical Research specialising in neuroprotection.
• 2006-2007: Consultant to Pfizer Canada Inc.

• Plenary lecturer: "The Centennial of the Neuron: A Decade of the Brain Event", National Academy of Sciences, Washington DC, USA, 1991.
• Elected Member of Academia Europaea, 1994.
• Plenary Lecturer, XIIth International Congress of the International Union of Pharmacology, Montreal, Canada, 1994.
• Astra Anglo-Nordic Pharmacology Prize, 1995.
• 9th McEwen prize lecturer, Queen’s University, Ontario, Canada, 1996.
• Crisp Lecturer, The Physiological Society, University of Leeds, 1996.
• Highly Cited Researcher in both Pharmacology and Neuroscience, 2002.
• Federation of European Neurosciences EJN Prize, 2006